Research Topics
| Norbert H HauelSummaryAffiliation: Boehringer Ingelheim Pharma KG Country: Germany Publications
| Collaborators |
Detail Information
Publications
Structure-based design of novel potent nonpeptide thrombin inhibitorsNorbert H Hauel
Boehringer Ingelheim Pharma KG, Research Division, Birkendorfer Strasse 65, D 88397 Biberach Riss, Germany
J Med Chem 45:1757-66. 2002..This zwitterionic molecule was converted into the double-prodrug 31 (BIBR 1048), which showed strong oral activity in different animal species. On the basis of these results, 31 was chosen for clinical development...
Heterocyclic thrombin inhibitors. Part 1: design and synthesis of amidino-phenoxy quinoline derivativesUwe J Ries
Department of Chemical Research, Boehringer Ingelheim Pharma KG, Birkendorfer Strasse 65, D 88397, Biberach Riss, Germany
Bioorg Med Chem Lett 13:2291-5. 2003..X-ray analyses of thrombin-bound inhibitors revealed that enzyme inhibition is mainly based on hydrophobic interactions...
Heterocyclic thrombin inhibitors. Part 2: quinoxalinone derivatives as novel, potent antithrombotic agentsUwe J Ries
Department of Chemical Research, Boehringer Ingelheim Pharma KG, Birkendorfer Strasse 65, D 88397, Biberach Riss, Germany
Bioorg Med Chem Lett 13:2297-302. 2003..Quinoxalinone derivatives as prototypes of dual thrombin and factor Xa inhibitors have been discovered. Nanomolar inhibition of both coagulation enzymes resulted in very potent antithrombotic activity in vitro...
